Description
A synthetic GNRHR antagonist (IC50 = 3 nM in HEK293 cells expressing the human receptor); inhibits the growth of WPMY-1, WPE1-NA22, BPH-1, and LNCaP prostate cell lines via caspase activation and induction of apoptosis (10 μM); decreases plasma testosterone levels in rats to castrate levels for the first 49 days post treatment (2 mg/kg); decreases tumor volume of Dunning R3327H prostate tumor flank implants in rats (1 mg/kg per month),
Formal name: N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide, monoacetate
Synonyms: FE 200486
Molecular weight: 1,692.30
CAS: 934016-19-0
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Product Type|Biochemicals|Small Molecule Activators|Caspases||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Endocrinology & Metabolism|Hormones & Receptors